West Pharmaceutical Services Stock Price and Value Analysis

West Pharmaceutical Services (NYSE:WST) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold West Pharmaceutical Services to reach your target.

Target type

WST Free Cash Flow Trend

Free Cash Flow trendline for WST
Free Cash Flow trendline for West Pharmaceutical Services
CSV

Based on historical returns, we believe that West Pharmaceutical Services can grow its free cash at a rate of about 7%. That's positive!

AdvantagesDisadvantages
  • This company is solid.
  • This company is making money at a decent rate.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company has a low dividend yield.

Inside the WST Numbers

WST Price
(West Pharmaceutical Services stock price per share)
$390.30
[?] WST Fair Price
(based on intrinsic value)
$92.92
[?] WST Safety Price (based on a variable margin of safety) $60.40
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 119% higher than other Healthcare stocks
[?] PE Ratio versus Industry 76% higher than other Medical Devices stocks
[?] Cash Yield 0.61%
[?] Free Cash Flow Jitter 37%
[?] Dividend Yield 0.22% (tax impact)
Shares Shorted 1,807,517

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,807,517 shares shorted. With 69,153,904 shares available for purchase and an average trading volume over the past 10 trading days of 526,020, it would take at least 3.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 105770 -3.6
2009 105770 15.9
2010 105770 33.4
2011 105770 28.2
2012 105770 79.1
2013 105770 110
2014 105770 70.6
2015 105770 88
2016 105770 80
2017 105770 124
2018 105770 159
2019 105770 234
2020 105770 331
2021 105770 426
2022 105770 535
2023 105770 536
2024 105770 363
2025 105770 442

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 11 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $5,032 million against net income of $3,846 million, or 1.31 times.

In 2025, operating cash flow was 1.53 times net income, compared with 1.84 times for the earliest three years (2008 to 2010).

In 2025, capital expenditures were $286 million, 37.9% of operating cash flow of $755 million, which leaves an estimated $469 million after capex. Across the 11 years with reported capex, it averaged 45.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 1.53, at least 0.25 under the 1.84 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 86 135 139 1.57
2009 72.6 138 105 1.90
2010 65.3 138 71.1 2.12
2018 207 289 105 1.39
2019 242 367 126 1.52
2020 346 473 174 1.36
2021 662 584 253 0.88
2022 586 724 285 1.24
2023 593 777 362 1.31
2024 493 653 377 1.33
2025 494 755 286 1.53

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $3,232 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $493 million, 15.2% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $1,869 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $195 million, 44.1% of estimated free cash flow of $442 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 80 35.8 52.2 88 110.0%
2017 124 39.1 74.4 114 91.5%
2018 159 42.1 70.8 113 71.1%
2019 234 45.1 83.1 128 54.7%
2020 331 48.1 116 164 49.4%
2021 426 51.1 137 188 44.2%
2022 535 54.1 203 257 48.0%
2023 536 57 438 495 92.3%
2024 363 59.1 561 620 170.7%
2025 442 61.2 134 195 44.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1,051 million in 2008 and $3,074 million in 2025, a compound annual growth rate of 6.5% over 17 years.

Revenue rose 6.3% from 2024 to 2025.

Our estimated free cash flow was $442 million in 2025, 14.4% of revenue. In 2008 the estimated margin was negative 0.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2008 1,051 -3.6 -0.3%
2009 1,056 15.9 1.5%
2010 1,105 33.4 3.0%
2011 1,192 28.2 2.4%
2012 1,266 79.1 6.2%
2013 1,368 110 8.0%
2014 1,421 70.6 5.0%
2015 1,400 88 6.3%
2016 1,509 80 5.3%
2017 1,599 124 7.8%
2018 1,717 159 9.2%
2019 1,840 234 12.7%
2020 2,147 331 15.4%
2021 2,832 426 15.0%
2022 2,887 535 18.5%
2023 2,950 536 18.2%
2024 2,893 363 12.6%
2025 3,074 442 14.4%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $791 million against total liabilities of $1,094 million, or 72.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 25.6% of total assets in 2025, compared with 54.4% in 2009, a decrease of 28.8 percentage points.

Stockholders equity was $3,176 million in 2025, compared with $579 million in 2009, a rise of 448.4%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 15.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 1,271 83.1 692 579
2010 1,294 110 669 626
2011 1,399 91.8 744 655
2012 1,564 162 835 729
2013 1,670 230 765 906
2014 1,670 255 713 957
2015 1,695 275 671 1,024
2016 1,717 203 599 1,118
2017 1,863 236 583 1,280
2018 1,979 337 583 1,396
2019 2,341 439 768 1,573
2020 2,794 616 939 1,855
2021 3,314 763 978 2,335
2022 3,617 894 932 2,685
2023 3,830 854 949 2,881
2024 3,643 485 961 2,682
2025 4,270 791 1,094 3,176

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $390.30, our model's value equals that price if free cash flow grows an average of 35.0 percent a year over the 10 projection years. Our model assumes 7.4 percent a year for this stock, so the price implies growth of 35.0 percent, which is above the 7.4 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 35.0 percent a year, free cash flow would grow about 20.1 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $170 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $312.24 31.3%
Current price $390.30 35.0%
20 percent above the current price $468.36 38.0%
Our model (stored fair price) $92.92 7.4%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Of the 18 fiscal years we can see for West Pharmaceutical Services under its current filer, 17 show positive free cash flow.

Our fair value estimate for West Pharmaceutical Services is $92.92, below its current price of $390.30.

Free cash flow from the first three years of data averaged $15.3 million, and from the last three $447 million: a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 37%.

Its dividend yield is 0.22%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 119% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 76% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to West Pharmaceutical Services, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
West Pharmaceutical Services (WST) 27,189 43.8 0.2% 0.6% 320% above
DexCom (DXCM) 29,582 31.2 - 0.1% 864% above
ResMed (RMD) 33,143 21.5 1.0% 1.2% 81% above
Baxter International (BAX) 13,135 - 0.2% 11.4% 61% below
Penumbra (PEN) 12,578 80.4 - - 781% above
Globus Medical (GMED) 8,861 16.5 - - 61% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.6% 24% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 105770.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 18 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: WST annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in WST

Does West Pharmaceutical Services have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: WST

This example shows how we apply the Trendshare checklist to WST: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 390.30
    • Market cap: $27B
    • EPS: 8.91
  2. Step 2 — Valuation checks

    • P/E: 43.805
    • FCF yield: 0.6%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.